CytoAgents Announces FDA Acceptance of IND Application for CTO1681 to Treat Cytokine Release Syndrom
Company Closes Financing and Prepares to Launch Phase 1b/2a Clinical TrialPITTSBURGH--(BUSINESS WIRE)--#CRS--CytoAgents, Inc., a clinical-stage biotechnology company developing a safe, effective treatment for Cytokine Release Syndrome (CRS), today announced that it has received a Study May Proceed letter from the U....